Edwards Lifesciences (EW) Liabilities from Discontinued Operations (2023 - 2025)

Edwards Lifesciences has reported Liabilities from Discontinued Operations for 3 years, with the latest figure at $2.3 million in Q3 2025.

• On a quarterly basis, Liabilities from Discontinued Operations rose 27.78% year-over-year to $2.3 million in Q3 2025; TTM through Sep 2025 was $2.3 million, a 27.78% increase from a year earlier, with the FY2024 full-year figure at $2.0 million, down 98.46% from the prior year.
• Liabilities from Discontinued Operations was $2.3 million for Q3 2025 at Edwards Lifesciences, roughly flat from $2.3 million in the prior quarter.
• The five-year high for Liabilities from Discontinued Operations was $129.5 million in Q4 2023, with the low at $1.8 million in Q3 2024.
• Average Liabilities from Discontinued Operations over 3 years is $35.3 million, with a median of $2.3 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Liabilities from Discontinued Operations tumbled 98.46% in 2024, then rose 27.78% in 2025.
• Over 3 years, Liabilities from Discontinued Operations stood at $129.5 million in 2023, then sank by 98.46% to $2.0 million in 2024, then rose by 15.0% to $2.3 million in 2025.
• The last three Liabilities from Discontinued Operations figures came in at $2.3 million (Q3 2025), $2.3 million (Q2 2025), and $2.3 million (Q1 2025), per Business Quant data.